ReviewThorax2016
Pulmonary fibrosis in the era of stratified medicine.
Review in Thorax, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Assessing theRMD open · 2025Pooled it
- Systematic review of drug effects in humans and models with surfactant-processing disease.European respiratory review : an official journal of the European Respiratory Society · 2018Pooled it
- Transcriptional factor KLF9 in pulmonary fibrosis: from molecular mechanisms to precision intervention-a narrative review.Journal of thoracic disease · 2026Review
- Review
- Genetic Associations in Non-Europeans with Pulmonary Fibrosis: Analysis of the All of Us Cohort.American journal of respiratory and critical care medicine · 2025Article
- Identification of predictive subphenotypes for clinical outcomes using real world data and machine learning.Nature communications · 2025Article
- Imperfect wound healing sets the stage for chronic diseases.Science (New York, N.Y.) · 2024Review
- Ficolin-1 ameliorates pulmonary fibrosis via directly binding to TGF-β1.Journal of translational medicine · 2024Article
- Diagnosis of interstitial lung diseases: from Averill A. Liebow to artificial intelligence.Journal of pathology and translational medicine · 2024Review
- Lung transplant recipients with telomere-mediated pulmonary fibrosis have increased risk for hematologic complications.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
- Proprotein Convertase Subtilisin/Kexin Type 6: A Risk Factor for Survival in Pulmonary Fibrosis?American journal of respiratory and critical care medicine · 2023Article
- Utility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosis.The European respiratory journal · 2022Observational
- Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants Supports Functional Roles ofAmerican journal of respiratory and critical care medicine · 2022Article
- Aberrant Multiciliogenesis in Idiopathic Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2022Article
- Review
- Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022Article
- Real-life prevalence of progressive fibrosing interstitial lung diseases.Scientific reports · 2021Article
- Lifetime risk of rheumatoid arthritis-associated interstitial lung disease inAnnals of the rheumatic diseases · 2021Observational
- Review
- Molecular Signatures of Idiopathic Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Both common and rare variants contribute to the genetic architecture of pulmonary fibrosis. Genome-wide association studies have identified common variants, or those with a minor allele frequency of >5%, that are linked to pulmonary fibrosis. The most widely replicated variant (rs35705950) is located in the promoter region of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.